New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 15, 2012
10:06 EDTCF, CELG, CBS, HAS, BAM, KO, TZOO, HRS, BMC, WFC, PGROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BMC Software (BMC) downgraded to Market Perform from Outperform at Raymond James... Brookfield (BAM) downgraded to Hold from Buy at Canaccord... Celgene (CELG) downgraded to Perform from Outperform at Oppenheimer... Harris (HRS) downgraded to Sell from Neutral at Lazard Capital... Hasbro (HAS) downgraded to Sell from Neutral at Goldman... Progressive (PGR) downgraded to Sell from Neutral at Citigroup... Travelzoo (TZOO) downgraded to Neutral from Buy at Ascendiant Capital... CBS (CBS) downgraded o Neutral from Overweight at Atlantic Equities... Wells Fargo (WFC) downgraded to Neutral from Market Perform at Leerink... Coca-Cola (KO) downgraded to Underperform from Outperform at CLSA... CF Industries (CF) downgraded to Hold from Buy at Dahlman Rose.
News For BMC;BAM;CELG;HRS;HAS;PGR;TZOO;CBS;WFC;KO;CF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 8, 2014
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
10:00 EDTCBSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTWFCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:52 EDTWFCWells Fargo downgraded to Market Perform from Outperform at Bernstein
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:23 EDTCBSUBS to hold a conference
42nd Annual Global Media & Communications Conference is being held in New York on December 8-10 with webcasted company presentations to begin on December 8 at 8 am; not all presentations may be webcasted. Webcast Link
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
06:35 EDTWFCValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
December 7, 2014
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:10 EDTCELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
12:26 EDTCBSCBS, DISH reach content carriage agreement
Subscribe for More Information
December 6, 2014
09:28 EDTCELGCelgene to hold an analyst and investor event
Analyst and Investor Event being held in conjunction with the American Society of Hematology's 56th Annual Meeting in San Francisco on December 7 at 11 pm. Webcast Link
December 5, 2014
16:55 EDTCBSCBS initiated with a Neutral at UBS
Subscribe for More Information
December 4, 2014
16:27 EDTCBSOn The Fly: Closing Wrap
Subscribe for More Information
15:58 EDTCBSStarz weighs alternate option after failing to find buyer, Bloomberg reports
Subscribe for More Information
10:43 EDTBAMBrookfield Property issues $1.8B of preferred equity to QIA for 9% stake
Subscribe for More Information
09:47 EDTCBSCBS, DISH not currently in negotiations, CNBC reports
Subscribe for More Information
09:45 EDTCBSCBS has no interest in acquisition of Starz, CNBC's Faber says
CBS (CBS) has no interest in pursuing an acquisition of Starz (STRZA), according to CNBC's David Faber, citing sources.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use